Chronic migraine: Comparison to acute migraine medications
Grosberg et al., Pain management, 2022:
Due to the high frequency of headaches, patients impacted by chronic migraine are struggling with poor quality of life, as well as elevated risk of medication overuse headache (which might cause migraine chronification). Thus, there is a need for non-pharmacological migraine treatments that are both effective and well tolerated.
This study was a post-hoc analysis of data from the open label multi-center clinical trial that demonstrated the efficacy and safety of Nerivio as an acute treatment for chronic migraine.
The study compared the effectiveness of Nerivio to that of standard-care medications (i.e., over-the-counter medications and triptans), based on data from 78 patients with chronic migraine who participated in the clinical trial. During the study, the participants treated their attacks with their preferred oral medication for the first four weeks, and then in the following four weeks treated their attacks with Nerivio (only). The participants rated their pain level prior to the treatment, and two hours after the beginning of the treatment, via the Nerivio app.
Results:
- Pain relief was achieved by 63% of the participants with Nerivio vs 49% with medications.
- Pain freedom was achieved by 32% of the participants with both Nerivio and medications.
- Pain freedom was achieved by 23% of the participants with Nerivio vs. 19% of the participants with medications.
- Consistency of pain freedom was achieved by the same number of subjects, 14.10% when using either Nerivio or medications.
Nerivio is an effective acute treatment for chronic migraine with non-inferior efficacy compared to current acute migraine therapies.
Source: Grosberg B, Rabany L, Vizel M, et al. Effectiveness comparison of remote electrical neuromodulation and standard-care medications for acute treatment of chronic migraine: a post-hoc analysis. Pain Management, 2022.
